化学科研者一站式服务平台

化合物简介

Dabrafenib (trade name Tafinlar, GSK2118436) is a drug for the treatment of cancers associated with a mutated version of the gene BRAF. Dabrafenib acts as an inhibitor of the associated enzyme B-Raf, which plays a role in the regulation of cell growth. Dabrafenib has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF(V600)-mutated metastatic melanoma.

基本信息

CAS:1195765-45-7
中文别名:达拉菲尼;
英文别名:Dabrafenib [USAN:INN];N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide;UNII-QGP4HA4G1B;Dabrafenib (USAN);Dabrafenib;Tafinlar;N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzene sulfonamide;
分子式:C23H20F3N5O2S2
分子量:519.562
精确质量:519.101
Psa:148.21
Logp:6.4488

编号系统

UNII:QGP4HA4G1B

物化性质

密度:1.4±0.1g/cm3
沸点:653.7±65.0°Cat760mmHg
闪点:349.2±34.3°C
蒸汽压:0.0±2.0mmHgat25°C
折射率:1.626
储存条件:-20°C

安全信息

生产方法及用途

合成路线

上游原料

下游产品

图谱

1H NMR : Predict


13C NMR : Predict


加载中...